C. Guly

发表

Adalimumab in juvenile-idiopathic arthritis-associated uveitis (JIA-U): 5-year follow-up of the Bristol participants of the SYCAMORE trial.

A. Dick, A. Ramanan, B. Hardwick, 2019, American journal of ophthalmology.

Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy

A. Dick, A. Ramanan, C. Guly, 2017, Pediatric Rheumatology.

Blau Syndrome-Associated Uveitis: Preliminary Results From an International Prospective Interventional Case Series.

J. Bertin, C. Wouters, A. Dick, 2017, American journal of ophthalmology.

Unilateral neuroretinitis secondary to Bartonella henselae infection

A. Ramanan, J. Bernatoniene, C. Guly, 2013, Archives of Disease in Childhood.

Uveitis and Juvenile Psoriatic Arthritis or Psoriasis.

J. Rosenbaum, A. Ramanan, C. Guly, 2018, American journal of ophthalmology.

Provide baseline and preliminary follow-up results in a 5-year longitudinal study of Blau syndrome

J. Bertin, C. Wouters, A. Dick, 2017 .

Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis

A. Ramanan, H. Smee, William D. Renton, 2019, Pediatric Rheumatology.

P185 Patient perceptions of physical activity following a diagnosis of giant cell arteritis: a multinational qualitative study

C. Hill, S. Mackie, J. Robson, 2020, Rheumatology.

Eye drop neurology

G. Plant, L. Bennetto, C. Guly, 2014, Practical Neurology.

APTITUDE Trial Management Group (2020). Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. The Lancet Rheumatology, 2(3), e135-e141.

A. Ramanan, C. Guly, A. Dick, 2020 .

Patient Perceptions of Physical Activity After a Diagnosis of Giant Cell Arteritis: Analysis of Multinational Qualitative Data

S. Mackie, J. Robson, E. Hoon, 2021, Arthritis care & research.

Investigation and management of uveitis

J. Forrester, C. Guly, 2010, BMJ : British Medical Journal.

Managing juvenile idiopathic arthritis-associated uveitis.

A. Dick, E. Carreño, A. Ramanan, 2016, Survey of ophthalmology.

Optic nerve and retinal features in uveitis associated with juvenile systemic granulomatous disease (Blau syndrome)

E. Carreño, A. Ramanan, J. Aróstegui, 2014, Acta ophthalmologica.

Outcome of adalimumab monotherapy in paediatric non-infectious uveitis

C. Guly, A. Ramanan, S. Clarke, 2023, Pediatric Rheumatology.

Acute Macular Neuroretinopathy Phenotype in Behçet's Disease.

E. Carreño, T. Burke, C. Guly, 2018, Ophthalmic surgery, lasers & imaging retina.

Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial

Ashley P Jones, A. Dick, T. Jaki, 2020, The Lancet Rheumatology.

Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)

S. de Bono, S. Keller, P. Quartier, 2021, Trials.

The Safety and Efficacy of Noncorticosteroid Triple Immunosuppressive Therapy in the Treatment of Refractory Chronic Noninfectious Uveitis in Childhood

A. Dick, A. Ramanan, E. Sen, 2014, The Journal of Rheumatology.

Adalimumab for childhood onset uveitis

A. Ramanan, C. Guly, 2018, Annals of the rheumatic diseases.

Childhood Chronic Idiopathic Uveitis in a Multicentre International Cohort.

I. Maccora, A. Ramanan, G. Simonini, 2023, Ocular immunology and inflammation.

Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial

T. Doan, Rebecca S. Overbury, D. Hawley, 2020, Trials.

Giant cell arteritis and transient visual loss

J. Olson, C. Guly, 2009, BMJ : British Medical Journal.

S100A12 and S100A8/9 proteins are biomarkers of articular disease activity in Blau syndrome

J. Bertin, C. Wouters, K. Foley, 2018, Rheumatology.

A career in medical ophthalmology

J. Olson, Graeme Williams, C. Guly, 2008, BMJ : British Medical Journal.

Patient perceptions of health-related quality of life in giant cell arteritis: international development of a disease-specific patient-reported outcome measure

J. Dawson, C. Hill, S. Mackie, 2021, Rheumatology.

Bilateral optic neuropathy associated with Castleman disease

C. Guly, S. Epps, L. Lowry, 2014, British journal of haematology.

A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)

Ashley P Jones, A. Dick, A. Ramanan, 2018, BMC Rheumatology.

APTITUDE Trial Management Group (2018). A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial). BMC Rheumatology , 2 (4).

Ashley P Jones, A. Dick, A. Ramanan, 2018 .

C. Guly, P. Steptoe, A. Dick, 2022, European journal of ophthalmology.

Prevention and treatment of age‐related macular degeneration

C. Guly, S. Horton, 2017 .

Investigation and management of uveitis

J. Forrester, C. Guly, 2010, BMJ : British Medical Journal.

Validation of a patient-reported outcome measure for giant cell arteritis

J. Dawson, S. Mackie, J. Robson, 2023, Rheumatology.

SAT0216 PATIENT PERCEPTIONS OF PHYSICAL ACTIVITY AFTER A DIAGNOSIS OF GIANT CELL ARTERITIS: A SECONDARY ANALYSIS OF MULTINATIONAL QUALITATIVE DATA

C. Hill, S. Mackie, J. Robson, 2019, Saturday, 15 June 2019.